Assay development for determination of tenofovir in human plasma by solid phase analytical derivatization and LC-MS/MS

Anthony T Podany, Curtis Sheldon, Daryl Grafelman, Corey M. Ohnmacht

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Background: A novel method was developed and validated to measure tenofovir in human plasma. Results/Methodology: This method employed solid phase analytical derivatization and analysis by LC-MS/MS. Stable-labeled internal standard was added to plasma samples followed by solid phase extraction. Retained analytes were derivatized on the solid phase extraction cartridges with a diazomethane solution to yield methyl-ester derivatives. Samples were analyzed using LC-MS/MS incorporating the use of a strong cation exchange column. The method was validated over a range of 5.00-750 ng/ml. The approach developed in this report for tenofovir could be applied to other analytes that share similar structural similarities. Conclusion: The tenofovir LC-MS/MS method was used to support a clinical study of over 400 samples with a 100% success rate.

Original languageEnglish (US)
Pages (from-to)3085-3095
Number of pages11
JournalBioanalysis
Volume7
Issue number24
DOIs
StatePublished - Dec 1 2015

Fingerprint

Tenofovir
Plasma (human)
Assays
Solid Phase Extraction
Diazomethane
Cations
Esters
Derivatives
Plasmas

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Clinical Biochemistry
  • Medical Laboratory Technology

Cite this

Assay development for determination of tenofovir in human plasma by solid phase analytical derivatization and LC-MS/MS. / Podany, Anthony T; Sheldon, Curtis; Grafelman, Daryl; Ohnmacht, Corey M.

In: Bioanalysis, Vol. 7, No. 24, 01.12.2015, p. 3085-3095.

Research output: Contribution to journalReview article

Podany, Anthony T ; Sheldon, Curtis ; Grafelman, Daryl ; Ohnmacht, Corey M. / Assay development for determination of tenofovir in human plasma by solid phase analytical derivatization and LC-MS/MS. In: Bioanalysis. 2015 ; Vol. 7, No. 24. pp. 3085-3095.
@article{3d7cef25446e45a4a0816e0c3bb449e1,
title = "Assay development for determination of tenofovir in human plasma by solid phase analytical derivatization and LC-MS/MS",
abstract = "Background: A novel method was developed and validated to measure tenofovir in human plasma. Results/Methodology: This method employed solid phase analytical derivatization and analysis by LC-MS/MS. Stable-labeled internal standard was added to plasma samples followed by solid phase extraction. Retained analytes were derivatized on the solid phase extraction cartridges with a diazomethane solution to yield methyl-ester derivatives. Samples were analyzed using LC-MS/MS incorporating the use of a strong cation exchange column. The method was validated over a range of 5.00-750 ng/ml. The approach developed in this report for tenofovir could be applied to other analytes that share similar structural similarities. Conclusion: The tenofovir LC-MS/MS method was used to support a clinical study of over 400 samples with a 100{\%} success rate.",
author = "Podany, {Anthony T} and Curtis Sheldon and Daryl Grafelman and Ohnmacht, {Corey M.}",
year = "2015",
month = "12",
day = "1",
doi = "10.4155/bio.15.220",
language = "English (US)",
volume = "7",
pages = "3085--3095",
journal = "Bioanalysis",
issn = "1757-6180",
publisher = "Future Science",
number = "24",

}

TY - JOUR

T1 - Assay development for determination of tenofovir in human plasma by solid phase analytical derivatization and LC-MS/MS

AU - Podany, Anthony T

AU - Sheldon, Curtis

AU - Grafelman, Daryl

AU - Ohnmacht, Corey M.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: A novel method was developed and validated to measure tenofovir in human plasma. Results/Methodology: This method employed solid phase analytical derivatization and analysis by LC-MS/MS. Stable-labeled internal standard was added to plasma samples followed by solid phase extraction. Retained analytes were derivatized on the solid phase extraction cartridges with a diazomethane solution to yield methyl-ester derivatives. Samples were analyzed using LC-MS/MS incorporating the use of a strong cation exchange column. The method was validated over a range of 5.00-750 ng/ml. The approach developed in this report for tenofovir could be applied to other analytes that share similar structural similarities. Conclusion: The tenofovir LC-MS/MS method was used to support a clinical study of over 400 samples with a 100% success rate.

AB - Background: A novel method was developed and validated to measure tenofovir in human plasma. Results/Methodology: This method employed solid phase analytical derivatization and analysis by LC-MS/MS. Stable-labeled internal standard was added to plasma samples followed by solid phase extraction. Retained analytes were derivatized on the solid phase extraction cartridges with a diazomethane solution to yield methyl-ester derivatives. Samples were analyzed using LC-MS/MS incorporating the use of a strong cation exchange column. The method was validated over a range of 5.00-750 ng/ml. The approach developed in this report for tenofovir could be applied to other analytes that share similar structural similarities. Conclusion: The tenofovir LC-MS/MS method was used to support a clinical study of over 400 samples with a 100% success rate.

UR - http://www.scopus.com/inward/record.url?scp=84949669029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949669029&partnerID=8YFLogxK

U2 - 10.4155/bio.15.220

DO - 10.4155/bio.15.220

M3 - Review article

VL - 7

SP - 3085

EP - 3095

JO - Bioanalysis

JF - Bioanalysis

SN - 1757-6180

IS - 24

ER -